Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference…
Company to participate in investor conferences in July and August The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website athttps://ir.zymeworks.com/events-and-presentations.Management will also participate in the following upcoming investor conferences: BTIG Virtual Biotechnology Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on July 29.Stifel Biotech Summer Summit: Zymeworks’ management...
Nasdaq GlobeNewswire
17/07/2025
Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops…
"This is the first international pharmacovigilance study focused specifically on a fixed-dose eye drop combining an antibiotic and an anti-inflammatory steroid," said Dr. Giorgio Ciprandi, senior author of the publication. "Its wide usage and favorable safety profile make of it a valuable option in the modern management of post-cataract patients'." "This is the first international pharmacovigilance study focused specifically on a fixed-dose eye drop combining an…
PR Newswire
17/07/2025
Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in…
Cardiovascular disease is the leading cause of mortality globally, with coronary artery bypass surgery being the most common cardiac surgery performed worldwide. CABG is an invasive procedure, often requiring multiple painful vein grafts with a high risk of complications. The global CABG market is projected to reach more than $20 Billion by 2035, driven by the growing prevalence of cardiovascular disease[i]. Cardiovascular disease is the leading cause of mortality globally, with coronary…
PR Newswire
17/07/2025
Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een…
Leuven, BELGIË – 17 juli 2025 – 8u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat het de financiering heeft verzekerd voor de overname van 72% van het kapitaal van Axiodis CRO, na een grondig due diligence-proces en de vervulling van alle opschortende voorwaarden…
Actusnews Wire
17/07/2025
Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing…
Leuven, BELGIUM – July 17, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces it has secured the financing for the acquisition of 72% of the share capital of Axiodis CRO, following a rigorous due diligence process and the fulfilment of all conditions precedent…
Actusnews Wire
17/07/2025
EAACI Leadership Reflects on Record-Breaking Congress 2025: A Pivotal Moment for…
“This year’s Congress was a turning point,” said Prof. Maria Torres, EAACI President. “We are entering an era where scientific innovation, equity in care, and environmental health must move forward together.” The programme featured over 250 hours of lectures, workshops, and symposia, covering groundbreaking advances in drug allergy, T2 inflammation, paediatric asthma, and hereditary angioedema. The Presidential Symposium tackled antimicrobial resistance through a One Health lens, while a...
Nasdaq GlobeNewswire
17/07/2025
Oxurion Secures Financing for the Acquisition of Axiodis CRO and Targets Closing…
Leuven, BELGIUM – July 17, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces it has secured the financing for the acquisition of 72% of the share capital of Axiodis CRO, following a rigorous due diligence process and the fulfilment of all conditions precedent…
Actusnews Wire
17/07/2025
One Biosciences Announces €15 Million Series A Financing to Advance Clinical…
Hedi Ben Brahim, CEO of One Biosciences, said: "This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market." Hedi Ben Brahim, CEO of One Biosciences, said: "This funding enables us to…
PR Newswire
17/07/2025
Oxurion verzekert financiering voor de overname van Axiodis CRO en beoogt een…
Leuven, BELGIË – 17 juli 2025 – 8u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat het de financiering heeft verzekerd voor de overname van 72% van het kapitaal van Axiodis CRO, na een grondig due diligence-proces en de vervulling van alle opschortende voorwaarden…
Actusnews Wire
17/07/2025
Pharming Group to report second quarter and first half 2025 financial results…
Leiden, the Netherlands, July 17, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a business update on Thursday, July 31, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CEST/07:30 am EDT. To participate in the conference call or to watch the live webcast, please...
Nasdaq GlobeNewswire
17/07/2025
Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial…
Financial Performance Financial Performance In Q2 2025, Hansa completed a successful capital raise with the support of new and existing shareholders. The funding will support two Phase 3 trial readouts in the second half of 2025 including the ConfIdeS US pivotal trial in kidney transplantation and GOOD-IDES-02 trial in anti-GBM. As part of a directed share issue, Hansa and NovaQuest entered into an amended debt agreement in which the Company offset US$14.9Mof outstanding debt...
PR Newswire
17/07/2025
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive…
Press ReleaseNicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 millionTiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa will assume full responsibility...
Nasdaq GlobeNewswire
17/07/2025
Essity: Interim Report Quarter 2, 2025
Quarter 2, 2025 Quarter 2, 2025 CEO'S COMMENTS For the second quarter, we achieved a positive organic sales growth and earnings ofSEK 4.7 bn. The quarter was dominated by a weak economy and an uncertain external environment, yielding limited volume growth. Our stable performance despite challenging market conditions demonstrates the strength of Essity's broad portfolio of essential solutions for better hygiene and health. Organic growth in a weak economy...
PR Newswire
17/07/2025
Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch…
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive Committee (ECN)After an extraordinary 22-year career at Novartis and more than 12 years as a member of the ECN, Harry Kirsch will retire and step down from the ECN on March 15, 2026 Basel, July 17, 2025– Novartis announced today the appointment of...
Nasdaq GlobeNewswire
17/07/2025
Novartis reports strong Q2 with double-digit sales growth and core margin…
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1, +12% USD) with core operating income 1up +21% (cc, +20% USD)Sales growth driven by continued strong performance fromKisqali(+64% cc),Entresto(+22% cc),Kesimpta(+33% cc),Scemblix(+79% cc),Leqvio(+61% cc) andPluvicto(+30% cc)Core operating income margin 1reached 42.2%, +340 basis points (cc), mainly driven by higher net sales Q2 operating income grew +25% (cc, +21% USD)…
Nasdaq GlobeNewswire
17/07/2025
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4…
ZURICH, SWITZERLAND, July 17, 2025 --VERAXA Biotech AG(“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, andVoyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities…
Nasdaq GlobeNewswire
17/07/2025
Press Release: Sanofi announces extension of Blueprint tender offer
Sanofi announces extension of Blueprint tender offerParis, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.001 per share of Blueprint Medicines Corporation for $129.00 per share in cash, plus one non-transferable contractual contingent right per share, representing the right to receive contingent payments of...
Nasdaq GlobeNewswire
17/07/2025
Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With…
Malaria is a serious infectious disease that affects more than 260 million people and claims approximately 600,000 lives worldwide each year. Over 90% of all malaria cases occur in Africa, with more than 70% of those affected being children under the age of five.3 Malaria is transmitted to humans by mosquitoes. While prevention and treatment methods are available, the efficacy of currently available vaccines remains limited, highlighting the urgent need for the development of vaccines with…
PR Newswire
17/07/2025
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty. The situation is further complicated by renewed regulatory scrutiny of mRNA vaccines at both federal and state levels, casting a shadow over ongoing cancer research efforts. Meanwhile, the incidence of cancers—especially gastrointestinal and colorectal cancers among younger populations—is on the rise, heightening the…
PR Newswire
17/07/2025
From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine
VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to…
PR Newswire
17/07/2025
Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period…
Key Takeaways from the Peanut Allergy Market Report Key Takeaways from the Peanut Allergy Market Report Discover which therapies are expected to grab the peanut allergy therapeutics market share @Peanut Allergy Market Report Peanut Allergy Market Dynamics The peanut allergy market dynamics are expected to change in the coming years.PALFORZIA, administered orally, offers a convenient and accessible treatment option compared totraditional SC, intradermal, and...
PR Newswire
16/07/2025
G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise
This report provides a comprehensive look at the global market for G protein-coupled receptor (GPCR) targeting technologies. It analyzes current market size and growth trends, and segments the market by assay type, product type application, and region. Assay types include functional and binding assays, while product types range from cell lines to detection kits. Applications span cancer, cardiovascular, CNS, and respiratory diseases. The report also covers regional markets across North America…
PR Newswire
16/07/2025
AAJ Capital 3 Corp. Announces Definitive Agreement for Qualifying Transaction…
The Definitive Agreement was negotiated at arm's length and sets out that, among other things, at closing of the Proposed Transaction, AAJ will issue 37,492,460 common shares in the capital of AAJ (the "AAJ Shares") to each of the shareholders of XRP in exchange for each ordinary share held in the capital of XRP (the "XRP Shares") rounded down to the nearest whole number, which is expected to result in a deemed transaction price of CAD$0.40 per AAJ Share. The Definitive…
PR Newswire
16/07/2025
Half-Year Report on Liquidity Contract with Invest Securities
Half-Year Report on Liquidity Contract with Invest SecuritiesNANTES, France - July 16, 2025, 6:00pm CET –Under the liquidity contract entrusted by OSE ImmunotherapeuticstoInvest Securities, the following assets were recorded on the liquidity account as ofJune 30, 2025 :27,792 shares 454,733.83 euros in cashAs a reminder, atDecember 31, 2024, the following assets were recorded on the liquidity account:42,457 shares332,969.24 euros in cashAs a reminder,...
Nasdaq GlobeNewswire
16/07/2025
Altri Comunicati
